Molybdenum cofactor deficiency (MoCD) is a rare autosomal-recessive metabolic disorder in which failure of molybdenum-cofactor synthesis disables several molybdenum-dependent enzymes. Toxic sulfite metabolites accumulate and can cause severe neonatal encephalopathy, seizures and rapid brain injury.
Typical presentation
Severe MoCD usually presents within hours or days of birth with seizures, abnormal tone, feeding difficulty and progressive encephalopathy.
The presentation can resemble hypoxic-ischaemic brain injury despite an uncomplicated pregnancy and delivery.
Why seizures are severe
Loss of sulfite oxidase activity causes accumulation of toxic sulfite-related metabolites, particularly S-sulfocysteine.
This contributes to neuronal injury and severe epileptic encephalopathy.
Types A, B and C
MoCD type A is usually caused by MOCS1 variants.
Type B involves MOCS2, while rarer forms involve later steps of molybdenum-cofactor synthesis such as GPHN.
Why subtype matters
Subtype is not merely descriptive. MoCD type A has a targeted replacement treatment that is not effective for downstream biosynthetic defects.
Biochemical clues
Typical findings include elevated urinary S-sulfocysteine, xanthine and hypoxanthine, with low serum uric acid.
These findings help distinguish MoCD from isolated sulfite oxidase deficiency.
MRI
Brain MRI can show changes resembling severe hypoxic-ischaemic injury.
Rapid progression makes early metabolic recognition essential.
Fosdenopterin
Fosdenopterin is a synthetic form of cyclic pyranopterin monophosphate, the intermediate missing in MoCD type A.
It bypasses the MOCS1 block and restores downstream molybdenum-cofactor synthesis.
Current regulatory status
In the United States, fosdenopterin is approved to reduce mortality risk in MoCD type A.
Availability and licensing differ internationally.
Why timing matters
Biochemical correction cannot reverse extensive brain injury that has already occurred.
Consensus guidance therefore emphasises starting treatment as rapidly as possible when type A is strongly suspected, with genetic confirmation pursued urgently.
Seizure treatment
Antiseizure medicines are used to control acute seizures, but they do not correct sulfite toxicity.
Disease-specific treatment and metabolic stabilisation are central.
Nutrition
Some specialist protocols use cysteine- or protein-restricted diets to reduce sulfur amino-acid load.
Such diets require close metabolic supervision to avoid malnutrition.
Types B and C
There is currently no equivalent approved replacement therapy for MoCD type B or C.
Management is supportive and metabolic, with ongoing research into targeted approaches.
Inheritance
MoCD is autosomal recessive.
Rapid molecular diagnosis also allows family counselling and prenatal or preimplantation testing where available.
Worldwide access
This is a time-critical disorder in which access to metabolic laboratories, rapid sequencing and fosdenopterin can determine outcome.
These resources remain very unevenly distributed worldwide.
The central point
MoCD type A is now a treatable neonatal metabolic encephalopathy, but treatment must begin before irreversible brain injury whenever possible.
Related reading
Metabolic Epilepsies →
Early Infantile DEE →
Sources
- 2024 consensus guidelines — isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies
- FDA — fosdenopterin prescribing information, revised 2026
Medical note: suspected MoCD is a metabolic emergency requiring specialist neonatal/metabolic assessment.
Evidence checked: September 2026.